Surprisingly, EF-24 treatment induced NFkB activity in K-562 cells, contrasting with previous reports of NFkB suppression in EF-24 treated lung, breast, ovarian, and cervical cancer cells [54]. This evidence concerns the gene NFKB1 and cervical cancer.